Nirogacestat - SpringWorks Therapeutics

Drug Profile

Nirogacestat - SpringWorks Therapeutics

Alternative Names: PF 3084014; PF-03084014

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Jules Bordet Institute; National Cancer Institute (USA); Pfizer
  • Class Amides; Antineoplastics; Imidazoles; Naphthalenes; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibroma; Pancreatic cancer
  • No development reported Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Discontinued Alzheimer's disease; Breast cancer

Most Recent Events

  • 05 Nov 2018 SpringWorks Therapeutics plans pivotal studies for desmoid tumors in H1 2019
  • 05 Sep 2018 Nirogacestat - SpringWorks Therapeutics receives Orphan Drug status for Fibroma in USA before September 2018
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top